

Program

Saturday 14 October

Satellite Event: MSD Breakfast Symposium

8.00am **Management of brain metastases in the era of immune checkpoint blockade**
Case presentations & panel discussion

Invited speaker: Victoria Atkinson, Queensland, Australia
Moderator: Rosalie Stephens, Auckland, New Zealand
Christopher Jackson, Otago, New Zealand
Peter Heppner, Auckland, New Zealand
Silvia Chiara Formenti, New York, USA

7.30am – 5.30pm Registration desk open

9.30am Conference opening

9.30am Mihi

9.35am President's welcome
Ben Lawrence, Auckland, New Zealand

Session 1: The tumour microenvironment in progression and therapy
Presented in partnership with the Maurice Wilkins Centre for Molecular Biodiscovery
Chairs: Andrew Macann, Francis Hunter

9.40am New aspects of tumour hypoxia biology
Invited speaker: Adrian Harris, Oxford, UK

10.10am Infiltrating immune cells that predict patient outcome
Invited speaker: Roslyn Kemp, Otago, New Zealand

10.40am Elevation of the p53 isoform, delta133p53 β , in glioblastoma with an immune suppressive signature and poorer prognosis
Tania Slatter, Otago, New Zealand

10.55am Distinct microbiome patterns associate with colorectal cancer molecular subtypes
Rachel Purcell, Otago, New Zealand

11.10am Morning tea amongst the exhibition

Session 2: Early-phase clinical trials
Presented in partnership with the European Society for Medical Oncology
Chairs: Michael Jameson, Anne O'Donnell

11.40am Title to be announced
Invited speaker: Josep Tabernero, Barcelona, Spain

12.10am Combination phase 1 oncology trials
Invited speaker: Mark McKeage, Auckland, New Zealand

12.25am Trials and tribulations
Invited speaker: Sanjeev Deva, Auckland, New Zealand

12.40pm An open-label, randomized cross-over bioavailability study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours
Paula Barlow, Auckland, New Zealand

12.55pm	Lunch amongst the exhibition
Session 3:	PHARMAC Young Researcher Awards Chairs: Richard Isaacs, Melanie McConnell
1:40pm	<p>Effects of exercise on the breast tumour microenvironment in hyperlipidaemic mice Linda Buss, Otago, New Zealand</p> <p>Investigating strategies to improve access to clinical trial opportunities in oncology in New Zealand – INSIGHT study Yeojeong So, Auckland, New Zealand</p> <p>Cancer-associated adipocytes alter proteomic expression of human breast cancer cells Rebekah Crane, Otago, New Zealand</p> <p>30 Day Mortality after Systemic Anticancer Treatment as a Real-World Quality of Care Indicator: The Northland experience Edmond Ang, Northland, New Zealand</p> <p>Informing Immunotherapy: Studying innate-like T cells in cancer Ellie-May Jarvis, Wellington, New Zealand</p> <p>Southern blood and cancer service FEC-D chemotherapy for early breast cancer, an audit of febrile neutropenia, toxicity and treatment interruption Tessa Morris, Otago, New Zealand</p> <p>Is there a role for ascorbate in regulating hypoxia factors in renal cell carcinoma? Christina Wolhrab, Otago, New Zealand</p> <p>Impact of Formalised Multidisciplinary Meeting on Referral Rate for Neoadjuvant Chemotherapy and Survival for Muscle Invasive Bladder Cancer: Auckland experience Michael Lee, Auckland, New Zealand</p> <p>The role of BCL6 in glioblastoma Nicole Jones, Wellington, New Zealand</p> <p>Predicting the risk of mortality and recurrence in breast cancer patients: A systematic review of risk prediction models Tung Phung, Auckland, New Zealand</p>
Session 4:	Clinical and scientific poster discussions Discussant: Michael Findlay, Auckland, New Zealand Discussant: Anita Dunbier, Otago, New Zealand
3.10pm	<p>The Women's Wellness after Cancer Program (WWACP): A multicentre randomised controlled trial of an e-enabled health promotion intervention Alexandra McCarthy, Auckland, New Zealand</p> <p>A retrospective audit of compliance with BRCA testing guidelines in the Medical Oncology clinic in Auckland City Hospital Ebert Wong, Auckland, New Zealand</p>
3.40pm	<p>The NETwork! Registry: Preliminary data suggests increasing incidence in a national study of neuroendocrine cancer in New Zealand (NZ) Kate Parker, Auckland, New Zealand</p> <p>Nanopore sequencing of full-length <i>BRCA1</i> mRNA transcripts reveals co-occurrence of known exon skipping events Logan Walker, Otago, New Zealand</p>
4.10pm	Afternoon tea amongst the exhibition
Session 5:	Tissue banking, molecular pathology and diagnostics Chairs: Peter Browett, Annette Lasham
4.40pm	<p>Title to be announced Invited speaker: Jorge Reis-Filho, New York, NY</p>
5.10pm	<p>Tissue Banking in New Zealand: Current priorities and future opportunities Speakers to be announced</p>
5.30pm	Open discussion of priorities in local tissue banking

Award:	Roche Translational Cancer Research Fellowship
5.50pm	Immunology in Clinical Research: Maximising patient data 2016 Recipient: Roslyn Kemp, Otago, New Zealand
5.55pm	Announcement of the 2017 Roche Translational Cancer Research Fellowship
6.00pm	NZSO annual general meeting
7.00pm	Conference dinner at the Auckland Art Gallery

Sunday 15 October

Satellite Event:	Roche Foundation Medicine Breakfast Symposium
8.00am	Genomics in clinical oncology – Hype or reality? Case presentations & panel discussion Moderator: Ben Lawrence, Auckland, New Zealand Sharon Pattison, Otago, New Zealand Cristin Print, Auckland, New Zealand Michelle Wilson, Auckland, New Zealand James Creeden, Medical Director Roche Foundation Medicine Asia Pacific
7.30am – 5.30pm	Registration desk open
9.10am	Incoming President's welcome Roslyn Kemp, Otago, New Zealand
Session 6:	Translational radiation oncology Chairs: Giuseppe Sasso, Bill Wilson
9.15am	Optimal radiation and immune checkpoint blockade combinations Invited speaker: Silvia Chiara Formenti, New York, USA
9.45am	Head & Neck Cancer: Remodeling the “wound healing response” during and post radiotherapy to influence both normal tissue effects and tumour control Invited speaker: Andrew Macann, Auckland, New Zealand
10.05am	Efficacy and sensitivity determinants of evofosfamide in head and neck squamous cell carcinoma Francis Hunter, Auckland, New Zealand
10.20am	Proteomic profiling of predictive biomarkers for hypoxia-activated prodrugs in head and neck squamous cell carcinomas Yongchuan Gu, Auckland, New Zealand
10.35am	Morning tea amongst the exhibition
Session 7:	Genomics, predisposition and precision oncology Chairs: Sharon Pattison, Andrew Shelling
11.00am	Drowning in Our Success: Post-GWAS studies of breast cancer risk Invited speaker: Georgia Chenevix-Trench, Queensland, Australia
11.30am	Genomics for Precision Oncology: How hard can it be? Invited speaker: Cristin Print, Auckland, New Zealand
11.50pm	Genomics in Haematological Malignancies: The future of genomics in solid tumors? Invited speaker: Stefan Bohlander, Auckland, New Zealand
12.10pm	Population genetic testing for breast cancer susceptibility Ian Campbell, Melbourne, Australia
12:25	Identification of cooperating genetic lesions in defined signaling pathways in CALM-AF10 driven murine leukaemia models Rhea Desai, Auckland, New Zealand
12.40pm	Lunch amongst the exhibition

Satellite Event: Professional Development Lunch Session

12.40pm **Career opportunities after a PhD in cancer research**
Andrew Shelling – Professor, University of Auckland
Andrew Kelly – Executive Director, BioPacific Partners
Stuart Ryan – Medical Manager, Roche NZ
Andy Shenk – CEO, Auckland UniServices Ltd
Paul O'Sullivan – Medical-Science Liaison, MSD

Award: NZSO Translational Research Award

1.25pm Presentation of the NZSO Translational Research Award

1.30pm NZSO Translational Research Award Lecture: To PI-3-Kinase and Back Again
Peter Shepherd, Auckland, New Zealand

Session 8: Drug discovery and novel approaches to therapy

Chairs: Mark McKeage, Bill Denny

2.00pm Discovery of hypoxia-selective kinase inhibitors
Invited speaker: Jeff Smaill, Auckland, New Zealand

2.20pm Converting toxic duocarmycin natural products to tumour-selective anticancer agents
Invited speaker: Moana Tercel, Auckland, New Zealand

2.40pm Next-generation hypoxic cell radiosensitisers: Nitroimidazole alkylsulfonamides
Michael Hay, Auckland, New Zealand

2.55pm Mitochondrial Transfer in Glioblastoma: Breaking bioenergetic boundaries
Mike Berridge, Wellington, New Zealand

3.10pm Afternoon tea amongst the exhibition

Session 9: Bruce Cain Memorial Lecture

Chairs: Ben Lawrence, Francis Hunter

3.30pm Title to be announced
Bruce Cain Memorial Lecturer: To be announced

4.25pm Closing remarks from the convener
Francis Hunter, Auckland, New Zealand

4.30pm Conference close
